Please ensure Javascript is enabled for purposes of website accessibility

A Big Disappointment Sends TG Therapeutics Stock Skidding 34% Today

By Todd Campbell - Updated Sep 25, 2018 at 11:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's pathway to the FDA just got a bit bumpier.

What happened

After reporting that it will no longer consider an accelerated pathway to approval of a combination drug therapy in clinical trials, TG Therapeutics (TGTX 1.84%) shares are tumbling 34% at 11:30 a.m. EDT on Tuesday.

So what

Until now, the company had been hoping that a phase 3 trial of its combination of ublituximab and umbralisib (U2) in chronic lymphocytic leukemia (CLL) would produce compelling enough overall response rates to allow it to file for accelerated approval.

A man hides his face in front of a wall with light bulbs drawn on it.


Today, that hope was dashed when management said independent monitors of the study couldn't conduct an interim analysis of overall response rate, a secondary trial endpoint, because the "data were not sufficiently mature."

No longer convinced that overall response rate can win over FDA regulators, TG Therapeutics will now rely solely on the study's primary endpoint -- progression-free survival -- to secure an approval. Unfortunately, data on progression-free survival won't be available until next year, at the earliest.

Now what

The monitors also reviewed the safety data and recommended the trial progress. The two-drug combination (U2) is being evaluated head to head against Gazyva, a Roche Holdings (RHHBY -0.54%) drug with $183 million (at current exchange rates) in sales in the first half of 2018, and chlorambucil, a chemotherapy.

If the doublet outperforms Gazyva, then TG Therapeutics has a shot at a therapy that could generate nine figures in annual revenue; however, given the uncertainty of achieving progression-free survival benefits and the delayed timeline to knowing how effective this combination really is, it's understandable that investors are disappointed.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

TG Therapeutics Stock Quote
TG Therapeutics
$4.99 (1.84%) $0.09
Roche Holding AG Stock Quote
Roche Holding AG
$42.99 (-0.54%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.